Phase 2 Double-blind Study of S-525606 in Patients with Japanese Cedar Pollinosis Using an Pollen Challenge Chamber
Phase 2
- Conditions
- Japanese cedar pollinosis
- Registration Number
- JPRN-jRCT2080222876
- Lead Sponsor
- Shionogi & Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Allergy test-positive patients who experienced symptoms of Japanese cedar pollinosis in the last two years or more.
Exclusion Criteria
Patients who potentially have allergic rhinitis, conjunctivitis or asthma caused by any allergens except for Japanese cedar pollen antigens.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy, safety
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Mechanism of action novel immunomodulators S-525606 Japanese cedar pollinosis allergic rhinitis
Pollen challenge chamber efficacy comparison novel therapies standard care Japanese cedar pollinosis
Biomarkers IgE eosinophils predicting treatment response Japanese cedar pollinosis pollen challenge studies
Safety profiles tolerability novel allergy treatments phase II trials Japanese cedar pollinosis
Shionogi allergy pipeline competitor analysis therapeutic landscape Japanese cedar pollinosis treatment